Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Targets
  4. Volume 26, Issue 2
  5. Article
Volume 26, Issue 2
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Remission failure and relapse numerate as one of the main problems in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that provide effective and safe induction accompanied by sustained remission seems to be urgent in clinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in various studies. RTX therapy offers several advantages to treating AAVs patients compared to other therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive therapy (IST) usage during both the induction of remission and maintenance phases. This reduction can lead to a lower rate of serious complications making RTX therapy a safer option. It seems that RTX may provide improved clinical outcomes in these patients mediated B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA), and myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In this regard, some uncertainties have been reported to validate the association between such depletion and clinical improvement, as suggested by other sources of autoreactive B cells that did not target with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of RTX may be required in patients with AAVs. In this narrative review, we aimed to insight better understand regarding the efficacy of RTX for effective induction and sustained remission in patients with AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients can lead to future targeted therapy.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdt/10.2174/0113894501323529240910015912
2024-09-23
2025-01-18

  • From This Site

    /content/journals/cdt/10.2174/0113894501323529240910015912
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FijołekJ. WiatrE. Antineutrophil cytoplasmic antibodies – Their role in pathogenesis, diagnosis and treatment monitoring of ANCA-associated vasculitis.Cent. Eur. J. Immunol.202045221822710.5114/ceji.2019.9249433456335
     [Google Scholar]
  2. HunterR.W. WelshN. FarrahT.E. GallacherP.J. DhaunN. ANCA associated vasculitis.Br. Med. J.2020369m107010.1136/bmj.m107032291255
     [Google Scholar]
  3. KoeningC.L. von HennigsI. Antineutrophil cytoplasmic antibody (ANCA) vasculitis: Pathophysiology, diagnosis, and the evolving treatment landscape.Am. J. Manag. Care20212715S267S27634473462
     [Google Scholar]
  4. WattsR.A. HatemiG. BurnsJ.C. MohammadA.J. Global epidemiology of vasculitis.Nat. Rev. Rheumatol.2022181223410.1038/s41584‑021‑00718‑834853411
     [Google Scholar]
  5. DaikelerT. KistlerA.D. MartinP.Y. VogtB. Huynh-DoU. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).Swiss Med. Wkly.2015145w1410310.4414/smw.2015.1410325658140
     [Google Scholar]
  6. RussellK.A. FassD.N. SpecksU. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener’s granulomatosis and microscopic polyangiitis.Arthritis Rheum.200144246346811229478
     [Google Scholar]
  7. ClainJ.M. Cartin-CebaR. FervenzaF.C. SpecksU. Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis.Ther. Adv. Musculoskelet. Dis.201462587410.1177/1759720X1351623924688606
     [Google Scholar]
  8. LiuL. LuH. ZouG. WangH. LiJ. YangY. ZhangJ. WangX. LiW. ZhuoL. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: A Chinese case series.BMC Nephrol.20232412810.1186/s12882‑023‑03075‑836755215
     [Google Scholar]
  9. MorelP. KarrasA. PorcherR. BelenfantX. AudardV. RafatC. HanounaG. BeaudreuilS. VilainC. HummelA. TerrierB. PilleboutE. GrohM. JouenneR. DhoteR. FainO. PonsoyeM. NoelN. LimalN. PuéchalX. Le JeunneC. GuillevinL. MouthonL. RégentA. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: The place of rituximab and plasma exchange?Rheumatology (Oxford)202261104056406410.1093/rheumatology/keac04635108368
     [Google Scholar]
  10. JainS. NaiduG.S.R.S.N.K. SharmaA. Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody–associated vasculitis: Comment on the article by Chung et al. Arthritis Rheumatol.202274354454510.1002/art.4200234694068
     [Google Scholar]
  11. LeeY.H. SongG.G. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized co.Int. J. Clin. Pharmacol. Ther.20226029710510.5414/CP20405334622770
     [Google Scholar]
  12. Martinez Del PeroM. ChaudhryA. JonesR.B. SivasothyP. JaniP. JayneD. B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: A cohort study.Clin. Otolaryngol.200934432833510.1111/j.1749‑4486.2009.01968.x19673980
     [Google Scholar]
  13. JonesR.B. Cohen TervaertJ.W. HauserT. LuqmaniR. MorganM.D. PehC.A. SavageC.O. SegelmarkM. TesarV. van PaassenP. WalshD. WalshM. WestmanK. JayneD.R.W. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.N. Engl. J. Med.2010363321122010.1056/NEJMoa090916920647198
     [Google Scholar]
  14. SpecksU. MerkelP.A. SeoP. SpieraR. LangfordC.A. HoffmanG.S. KallenbergC.G. St ClairE.W. FesslerB.J. DingL. VivianoL. TchaoN.K. PhippardD.J. AsareA.L. LimN. IkleD. JepsonB. BrunettaP. AllenN.B. FervenzaF.C. GeethaD. KeoghK. KissinE.Y. MonachP.A. PeikertT. StegemanC. YtterbergS.R. MuellerM. SejismundoL.P. MierasK. StoneJ.H. Efficacy of remission-induction regimens for ANCA-associated vasculitis.N. Engl. J. Med.2013369541742710.1056/NEJMoa121327723902481
     [Google Scholar]
  15. AzarL. SpringerJ. LangfordC.A. HoffmanG.S. Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center study.Arthritis Rheumatol.201466102862287010.1002/art.3874424943239
     [Google Scholar]
  16. LionakiS. FragoulisGE. VenetsanopoulouA. VlachoyiannopoulosP. BoletisJN. TzioufasAG. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.Clin. Exp. Rheumatol201735(Suppl 103)S155S164
     [Google Scholar]
  17. RoccatelloD. SciasciaS. RossiD. AlpaM. NarettoC. RussoA. MenegattiE. BaldovinoS. Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis.Am. J. Nephrol.201134217518010.1159/00032953521757891
     [Google Scholar]
  18. PugnetG. PagnouxC. TerrierB. PerrodeauE. PuéchalX. KarrasA. KhouatraC. AumaîtreO. CohenP. MaurierF. DecauxO. NinetJ. GobertP. QuemeneurT. Blanchard-DelaunayC. GodmerP. CarronP.L. HatronP.Y. LimalN. HamidouM. DucretM. DaugasE. PapoT. BonnotteB. MahrA. RavaudP. MouthonL. GuillevinL. Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life.Clin. Exp. Rheumatol.2016343S54S5927049404
     [Google Scholar]
  19. YatesM. WattsR.A. BajemaI.M. CidM.C. CrestaniB. HauserT. HellmichB. HolleJ.U. LaudienM. LittleM.A. LuqmaniR.A. MahrA. MerkelP.A. MillsJ. MooneyJ. SegelmarkM. TesarV. WestmanK. VaglioA. YalçındağN. JayneD.R. MukhtyarC. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Ann. Rheum. Dis.20167591583159410.1136/annrheumdis‑2016‑20913327338776
     [Google Scholar]
  20. MontanteA. Le BrasA. PagnouxC. PerrodeauE. RavaudP. TerrierB. GuillevinL. Durand-ZaleskiI. Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.Clin. Exp. Rheumatol.201937213714331162031
     [Google Scholar]
  21. RheeE.P. LaliberteK.A. NilesJ.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.Clin. J. Am. Soc. Nephrol.2010581394140010.2215/CJN.0882120920498238
     [Google Scholar]
  22. MiloslavskyE.M. SpecksU. MerkelP.A. SeoP. SpieraR. LangfordC.A. HoffmanG.S. KallenbergC.G. St ClairE.W. TchaoN.K. DingL. IkléD. VillarealM. LimN. BrunettaP. FervenzaF.C. MonachP.A. StoneJ.H. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.Arthritis Rheumatol.20156761629163610.1002/art.3910425776953
     [Google Scholar]
  23. HolleJ.U. DubrauC. HerlynK. HellerM. AmbroschP. NoelleB. Reinhold-KellerE. GrossW.L. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations.Ann. Rheum. Dis.201271332733310.1136/ard.2011.15360122021864
     [Google Scholar]
  24. TakeyamaY. OnoN. ShirahamaY. InoueY. TanakaA. UedaN. NishimuraN. NaganoS. UchinoA. MiyamuraT. OryojiK. InoueH. MaruyamaA. OtaS. YoshizawaS. SawabeT. HimuroN. MiyakeK. KimotoY. HoriuchiT. MitomaH. NiiroH. TakamoriA. TadaY. Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan.Mod. Rheumatol.202131240841610.1080/14397595.2020.179077832615836
     [Google Scholar]
  25. WeinerM. GohS.M. MohammadA.J. HruškováZ. TannaA. SharpP. KangA. BruchfeldA. SelgaD. ChocováZ. WestmanK. ErikssonP. HarperL. PuseyC.D. TesařV. SalamaA.D. SegelmarkM. Effect of treatment on damage and hospitalization in elderly patients with microscopic polyangiitis and granulomatosis with polyangiitis.J. Rheumatol.202047458058810.3899/jrheum.19001931308208
     [Google Scholar]
  26. MendelA. PagnouxC. Use of rituximab for the treatment of antineutrophil cytoplasm antibody–associated vasculitis in Canada, 2010–2020.J. Rheumatol.202148111755175610.3899/jrheum.21053734470792
     [Google Scholar]
  27. JamesK.E. XiaoR. MerkelP.A. WeissP.F. Variation in the treatment of children hospitalized with antineutrophil cytoplasmic antibody–associated vasculitis in the US.Arthritis Care Res. (Hoboken)20176991377138310.1002/acr.2314227813340
     [Google Scholar]
  28. Cartin-CebaR. Diaz-CaballeroL. Al-QadiM.O. TryfonS. FervenzaF.C. YtterbergS.R. SpecksU. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody–associated vasculitis: Predictors of respiratory failure and clinical outcomes.Arthritis Rheumatol.20166861467147610.1002/art.3956226713723
     [Google Scholar]
  29. ChasseurP. BlockmansD. von FrenckellC. NicolasJ-B. RegniersC. VandergheynstF. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-associated vasculitis in a Belgian multicenter cohort.Acta Clin. Belg.202075316316910.1080/17843286.2019.157804130767717
     [Google Scholar]
  30. McAdooS.P. Medjeral-ThomasN. GopaluniS. TannaA. MansfieldN. GallifordJ. GriffithM. LevyJ. CairnsT.D. JayneD. SalamaA.D. PuseyC.D. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.Nephrol. Dial. Transplant.2019341637310.1093/ndt/gfx37829462348
     [Google Scholar]
  31. CharlesP. NéelA. TieuliéN. HotA. PugnetG. DecauxO. MarieI. KhellafM. KahnJ.E. KarrasA. ZizaJ.M. DelignyC. TchérakianC. GuillevinL. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.Rheumatology (Oxford)201453353253910.1093/rheumatology/ket38124282319
     [Google Scholar]
  32. PendergraftW.F.III CortazarF.B. WengerJ. MurphyA.P. RheeE.P. LaliberteK.A. NilesJ.L. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.Clin. J. Am. Soc. Nephrol.20149473674410.2215/CJN.0734071324626432
     [Google Scholar]
  33. CalichA.L. PuéchalX. PugnetG. LondonJ. TerrierB. CharlesP. MouthonL. GuillevinL. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients.J. Autoimmun.20145013514110.1016/j.jaut.2014.03.00224703438
     [Google Scholar]
  34. BénardV. FarhatC. Zarandi-NowrooziM. DurandM. CharlesP. PuéchalX. GuillevinL. PagnouxC. MakhzoumJ.P. Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody–associated vasculitis: Systematic review and meta-analysis.ACR Open Rheumatol.20213748449410.1002/acr2.1127434114739
     [Google Scholar]
  35. SmithR.M. JonesR.B. GuerryM.J. LaurinoS. CatapanoF. ChaudhryA. SmithK.G.C. JayneD.R.W. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheum.201264113760376910.1002/art.3458322729997
     [Google Scholar]
  36. KnightA. HallenbergH. BaecklundE. Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis - A case series.Clin. Rheumatol.201433684184810.1007/s10067‑013‑2351‑y23959445
     [Google Scholar]
  37. PuéchalX. IudiciM. CalichA.L. VivotA. TerrierB. RégentA. CohenP. JeunneC.L. MouthonL. RavaudP. GuillevinL. Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: A single-centre cohort study on 114 patients.Rheumatology (Oxford)201958340140910.1093/rheumatology/key11729722877
     [Google Scholar]
  38. ThietartS KarrasA AugustoJ-F PhilipponnetC CarronP-L DelbrelX MesbahR BlaisonG DuffauP El KarouiK Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody-associated vasculitis.JAMA Netw. Open202257e22209210.1001/jamanetworkopen.2022.20925
     [Google Scholar]
  39. BesadaE. KoldingsnesW. NossentJ.C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre.Rheumatology (Oxford)201352112041204710.1093/rheumatology/ket25723934313
     [Google Scholar]
  40. HarperL. MorganM.D. WalshM. HoglundP. WestmanK. FlossmannO. TesarV. VanhilleP. GrootK. LuqmaniR. Flores-SuarezL.F. WattsR. PuseyC. BruchfeldA. RasmussenN. BlockmansD. SavageC.O. JayneD. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up.Ann. Rheum. Dis.201271695596010.1136/annrheumdis‑2011‑20047722128076
     [Google Scholar]
  41. StoneJ.H. MerkelP.A. SpieraR. SeoP. LangfordC.A. HoffmanG.S. KallenbergC.G. St ClairE.W. TurkiewiczA. TchaoN.K. WebberL. DingL. SejismundoL.P. MierasK. WeitzenkampD. IkleD. Seyfert-MargolisV. MuellerM. BrunettaP. AllenN.B. FervenzaF.C. GeethaD. KeoghK.A. KissinE.Y. MonachP.A. PeikertT. StegemanC. YtterbergS.R. SpecksU. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N. Engl. J. Med.2010363322123210.1056/NEJMoa090990520647199
     [Google Scholar]
  42. McGregorJG HoganSL KotzenES PoultonCJ HuY Negrete-LopezR KiddJM KatsanosSL BunchDO NachmanPH FalkRJ Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Nephrol. Dial. Transplant.201530suppl 1i123i13110.1093/ndt/gfv076
     [Google Scholar]
  43. AlbericiF. SmithR.M. JonesR.B. RobertsD.M. WillcocksL.C. ChaudhryA. SmithK.G.C. JayneD.R.W. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.Rheumatology (Oxford)20155471153116010.1093/rheumatology/keu45225477054
     [Google Scholar]
  44. Cartin-CebaR. GolbinJ.M. KeoghK.A. PeikertT. Sánchez-MenéndezM. YtterbergS.R. FervenzaF.C. SpecksU. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): Ten-year experience at a single center.Arthritis Rheum.201264113770377810.1002/art.3458422730028
     [Google Scholar]
  45. MansfieldN. HamourS. HabibA.M. TarziR. LevyJ. GriffithM. CairnsT. CookH.T. PuseyC.D. SalamaA.D. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis.Nephrol. Dial. Transplant.201126103280328610.1093/ndt/gfr12721414973
     [Google Scholar]
  46. Braun-MoscoviciY. Butbul-AvielY. GuralnikL. ToledanoK. MarkovitsD. RozinA. NahirM.A. Balbir-GurmanA. Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experience.Rheumatol. Int.20133361495150410.1007/s00296‑012‑2587‑x23239037
     [Google Scholar]
  47. Roubaud-BaudronC. PagnouxC. Méaux-RuaultN. GraslandA. ZoulimA. Le GuenJ. Prud’HommeA. BienvenuB. de MenthonM.A.T.H.I.L.D.E. CampsS. Le GuernV. AoubaA. CohenP. MouthonL. GuillevinL. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis.J. Rheumatol.201239112513010.3899/jrheum.11014322089465
     [Google Scholar]
  48. JonesR.B. FerraroA.J. ChaudhryA.N. BroganP. SalamaA.D. SmithK.G.C. SavageC.O.S. JayneD.R.W. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheum.20096072156216810.1002/art.2463719565480
     [Google Scholar]
  49. MittalS. NaiduG.S.R.S.N.K. JhaS. RathiM. NadaR. MinzR.W. SharmaK. DhirV. JainS. SharmaA. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis - A real-life experience.Clin. Rheumatol.202140264565110.1007/s10067‑020‑05261‑732656662
     [Google Scholar]
  50. BrihayeB. AoubaA. PagnouxC. CohenP. LacassinF. GuillevinL. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: A study on 8 patients.Clin. Exp. Rheumatol.2007251S23S2717428359
     [Google Scholar]
  51. ReesF. YazdaniR. LanyonP. Long-term follow-up of different refractory systemic vasculitides treated with rituximab.Clin. Rheumatol.20113091241124510.1007/s10067‑011‑1756‑821523362
     [Google Scholar]
  52. CharlesP. TerrierB. PerrodeauÉ. CohenP. FaguerS. HuartA. HamidouM. AgardC. BonnotteB. SamsonM. KarrasA. Jourde-ChicheN. LifermannF. GobertP. Hanrotel-SaliouC. GodmerP. Martin-SilvaN. PugnetG. MatignonM. AumaitreO. ViallardJ.F. MaurierF. Meaux-RuaultN. RivièreS. SibiliaJ. PuéchalX. RavaudP. MouthonL. GuillevinL. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).Ann. Rheum. Dis.20187781143114910.1136/annrheumdis‑2017‑21287829695500
     [Google Scholar]
  53. MiloslavskyE.M. SpecksU. MerkelP.A. SeoP. SpieraR. LangfordC.A. HoffmanG.S. KallenbergC.G.M. St ClairE.W. TchaoN.K. VivianoL. DingL. IkléD. VillarrealM. JepsonB. BrunettaP. AllenN.B. FervenzaF.C. GeethaD. KeoghK. KissinE.Y. MonachP.A. PeikertT. StegemanC. YtterbergS.R. StoneJ.H. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheumatol.201466113151315910.1002/art.3878825047592
     [Google Scholar]
  54. LovricS. ErdbrueggerU. KümpersP. WoywodtA. KoeneckeC. WedemeyerH. HallerH. HaubitzM. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: A single-centre experience with 15 patients.Nephrol. Dial. Transplant.200824117918510.1093/ndt/gfn43018685144
     [Google Scholar]
  55. TieuJ. SmithR. BasuN. BroganP. D’CruzD. DhaunN. FlossmannO. HarperL. JonesR.B. LanyonP.C. LuqmaniR.A. McAdooS.P. MukhtyarC. PearceF.A. PuseyC.D. RobsonJ.C. SalamaA.D. SmythL. WattsR.A. WillcocksL.C. JayneD.R.W. Rituximab for maintenance of remission in ANCA-associated vasculitis: Expert consensus guidelines-Executive summary.Rheumatology (Oxford)202059472773110.1093/rheumatology/kez63232096542
     [Google Scholar]
  56. AriesP.M. HellmichB. VoswinkelJ. BothM. NölleB. Holl-UlrichK. LamprechtP. GrossW.L. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations.Ann. Rheum. Dis.200565785385810.1136/ard.2005.04442016269425
     [Google Scholar]
  57. OokaS. MaedaA. ItoH. OmataM. YamadaH. OzakiS. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener’s granulomatosis: A case report.Mod. Rheumatol.2009191808310.3109/s10165‑008‑0119‑z18806927
     [Google Scholar]
  58. KhanA. LawsonC.A. QuinnM.A. IsdaleA.H. GreenM.J. Successful treatment of ANCA-negative wegener’s granulomatosis with rituximab.Int. J. Rheumatol.201020101210.1155/2010/84606321049001
     [Google Scholar]
  59. LandJ. AbdulahadW.H. ArendsS. SandersJ.S.F. StegemanC.A. HeeringaP. RutgersA. Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis.PLoS One2017128e018254910.1371/journal.pone.018254928771641
     [Google Scholar]
  60. ThielJ. RizziM. EngesserM. DufnerA.K. TroiloA. LorenzettiR. VollR.E. VenhoffN. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: A longitudinal observational study on 120 patients.Arthritis Res. Ther.201719110110.1186/s13075‑017‑1306‑028521808
     [Google Scholar]
  61. UrlaubD. ZhaoS. BlankN. BergnerR. ClausM. TretterT. LorenzH.M. WatzlC. MerktW. Activation of natural killer cells by rituximab in granulomatosis with polyangiitis.Arthritis Res. Ther.201921127710.1186/s13075‑019‑2054‑031829278
     [Google Scholar]
  62. SmithR.M. JonesR.B. SpecksU. BondS. NodaleM. AljayyousiR. AndrewsJ. BruchfeldA. CamilleriB. CaretteS. CheungC.K. DerebailV. DoultonT. ForbessL. FujimotoS. FurutaS. Gewurz-SingerO. HarperL. Ito-IharaT. KhalidiN. KlockeR. KoeningC. KomagataY. LangfordC. LanyonP. LuqmaniR.A. MakinoH. McAlearC. MonachP. MorelandL.W. MynardK. NachmanP. PagnouxC. PearceF. PehC.A. PuseyC. RanganathanD. RheeR.L. SpieraR. SreihA.G. TesarV. WaltersG. WeismanM.H. WroeC. MerkelP. JayneD. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.Ann. Rheum. Dis.20207991243124910.1136/annrheumdis‑2019‑21686332581088
     [Google Scholar]
  63. FerraroA.J. SmithS.W. NeilD. SavageC.O.S. Relapsed Wegener’s granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent ‘depletion’ of peripheral blood.Nephrol. Dial. Transplant.20082393030303210.1093/ndt/gfn31818586761
     [Google Scholar]
  64. VenhoffN. EffelsbergN.M. SalzerU. WarnatzK. PeterH.H. LebrechtD. SchlesierM. VollR.E. ThielJ. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.PLoS One201275e3762610.1371/journal.pone.003762622629432
     [Google Scholar]
  65. TsuboiK. NoguchiK. KitanoM. FurukawaT. HashimotoT. AzumaN. MatsuiK. Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis.Immunol. Med.202245423824310.1080/25785826.2022.209459235802795
     [Google Scholar]
  66. VenhoffN. NiessenL. KreuzalerM. RolinkA.G. HässlerF. RizziM. VollR.E. ThielJ. Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.Autoimmunity201447640140810.3109/08916934.2014.91417424798501
     [Google Scholar]
  67. SpringerJ.M. FunkR.S. Dose-dependent pharmacological response to rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis.J. Rheumatol.202148111718172410.3899/jrheum.21036134334366
     [Google Scholar]
  68. DieguesA. TavaresJ. SáD. OliveiraJ. FernandesD. SantosJ. RochaG. Granulomatosis with polyangiitis: Recurrence or treatment consequences?Eur. J. Case Rep. Intern. Med.20218400244833987124
     [Google Scholar]
  69. van DamL.S. OskamJ.M. KamerlingS.W.A. ArendsE.J. BredewoldO.W. BerkowskaM.A. van DongenJ.J.M. RabelinkT.J. van KootenC. TengY.K.O. Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients.Front. Immunol.20201156673210.3389/fimmu.2020.56673233384685
     [Google Scholar]
  70. UnizonyS. LimN. PhippardD.J. CareyV.J. MiloslavskyE.M. TchaoN.K. IkléD. AsareA.L. MerkelP.A. MonachP.A. SeoP. St ClairE.W. LangfordC.A. SpieraR. HoffmanG.S. KallenbergC.G. SpecksU. StoneJ.H. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheumatol.201567253554410.1002/art.3891625332071
     [Google Scholar]
  71. ChocovaZ. HruskovaZ. MareckovaH. SvobodovaB. DuskovaD. BednarovaV. JancovaE. RysavaR. TesarV. Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters.Clin. Rheumatol.201534110711510.1007/s10067‑014‑2816‑725388644
     [Google Scholar]
  72. Martinez ValenzuelaL. Bordignon DraibeJ. Fulladosa OliverasX. Bestard MatamorosO. Cruzado GarritJ.M. Torras AmbrósJ. T-lymphocyte in ANCA-associated vasculitis: What do we know? A pathophysiological and therapeutic approach.Clin. Kidney J.201912450351110.1093/ckj/sfz02931384441
     [Google Scholar]
  73. MéletJ. MullemanD. GoupilleP. RibourtoutB. WatierH. ThibaultG. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.Arthritis Rheum.201365112783279010.1002/art.3810723918413
     [Google Scholar]
  74. BesadaE. NossentJ.C. CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in Granulomatosis with polyangiitis patients.PeerJ20164e248710.7717/peerj.248727688979
     [Google Scholar]
  75. ZhaoY. LutaloP.M.K. ThomasJ.E. SangleS. ChoongL.M. TylerJ.R. TreeT. SpencerJ. D’CruzD.P. Circulating T follicular helper cell and regulatory T cell frequencies are influenced by B cell depletion in patients with granulomatosis with polyangiitis.Rheumatology (Oxford)201453462163010.1093/rheumatology/ket40624357812
     [Google Scholar]
  76. MerktW. ClausM. BlankN. HundemerM. CerwenkaA. LorenzH.M. WatzlC. Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells.Arthritis Res. Ther.201618120410.1186/s13075‑016‑1098‑727624647
     [Google Scholar]
  77. MerktW. LorenzH.M. WatzlC. Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting.Arthritis Res. Ther.201618120610.1186/s13075‑016‑1101‑327629249
     [Google Scholar]
  78. KishimotoT HibiM MurakamiM NarazakiM SaitoM TagaT The molecular biology of interleukin 6 and its receptor.Ciba Foundation Symposium 167 - Polyfunctional Cytokines: IL-6 and LIF BockGR. MarshJ. WiddowsK. 1992516
     [Google Scholar]
  79. WangQ. van TimmerenM.M. PetersenA.H. YuanJ. MoserJ. BrouwerE. WestraJ. BootsA.M.H. HeeringaP. Age-determined severity of anti-myeloperoxidase autoantibody-mediated glomerulonephritis in mice.Nephrol. Dial. Transplant.201732225426428186568
     [Google Scholar]
  80. BertiA. WarnerR. JohnsonK. CornecD. SchroederD.R. KabatB.F. LangfordC.A. KallenbergC.G.M. SeoP. SpieraR.F. St ClairE.W. FervenzaF.C. StoneJ.H. MonachP.A. SpecksU. MerkelP.A. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.J. Autoimmun.201910510230210.1016/j.jaut.2019.07.00131320177
     [Google Scholar]
  81. NatarajaA. MukhtyarC. HellmichB. LangfordC. LuqmaniR. Outpatient assessment of systemic vasculitis.Best Pract. Res. Clin. Rheumatol.200721471373210.1016/j.berh.2007.01.00417678832
     [Google Scholar]
  82. BoomsmaM.M. StegemanC.A. Van Der LeijM.J. OostW. HermansJ. KallenbergC.G.M. LimburgP.C. TervaertJ.W.C. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study.Arthritis Rheum.20004392025203311014352
     [Google Scholar]
  83. JoshiL. LightmanS.L. SalamaA.D. ShirodkarA.L. PuseyC.D. TaylorS.R.J. Rituximab in refractory ophthalmic Wegener’s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective.Ophthalmology2011118122498250310.1016/j.ophtha.2011.06.00921907416
     [Google Scholar]
  84. van DamL.S. DirikgilE. BredewoldE.W. RayA. BakkerJ.A. van KootenC. RabelinkT.J. TengY.K.O. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.Nephrol. Dial. Transplant.20213681408141710.1093/ndt/gfaa06632601673
     [Google Scholar]
  85. McClureM.E. WasonJ. GopaluniS. TieuJ. SmithR.M. JayneD.R. JonesR.B. Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis.J. Clin. Rheumatol.201925521722310.1097/RHU.000000000000103030896460
     [Google Scholar]
  86. FinkielmanJ.D. MerkelP.A. SchroederD. HoffmanG.S. SpieraR. St ClairE.W. DavisJ.C.Jr McCuneW.J. LearsA.K. YtterbergS.R. HummelA.M. VissM.A. PeikertT. StoneJ.H. SpecksU. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.Ann. Intern. Med.2007147961161910.7326/0003‑4819‑147‑9‑200711060‑0000517975183
     [Google Scholar]
  87. RasmussenN. SalmelaA. EkstrandA. de GrootK. GregoriniG. Cohen TervaertJ.W. GrossW.L. WiikA. JayneD.R. Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener’s) may reflect treatment rather than disease activity.Clin. Exp. Rheumatol.2013311S38S4423380137
     [Google Scholar]
  88. UnizonyS. VillarrealM. MiloslavskyE.M. LuN. MerkelP.A. SpieraR. SeoP. LangfordC.A. HoffmanG.S. KallenbergC.M. St ClairE.W. IkleD. TchaoN.K. DingL. BrunettaP. ChoiH.K. MonachP.A. FervenzaF. StoneJ.H. SpecksU. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.Ann. Rheum. Dis.20167561166116910.1136/annrheumdis‑2015‑20807326621483
     [Google Scholar]
  89. Md YusofM.Y. VitalE.M. DasS. DassS. ArumugakaniG. SavicS. RawstronA.C. EmeryP. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: Identifying B cell biomarkers for relapse to guide retreatment decisions.Ann. Rheum. Dis.20157491734173810.1136/annrheumdis‑2014‑20649625854586
     [Google Scholar]
  90. MiyazakiY. NakayamadaS. KuboS. IshikawaY. YoshikawaM. SakataK. IwataS. MiyagawaI. NakanoK. TanakaY. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.Arthritis Res. Ther.202022114110.1186/s13075‑020‑02215‑x32539843
     [Google Scholar]
  91. BunchD.O. MendozaC.E. AybarL.T. KotzenE.S. ColbyK.R. HuY. HoganS.L. PoultonC.J. SchmitzJ.L. FalkR.J. NachmanP.H. PendergraftW.F. McGregorJ.G. Gleaning relapse risk from B cell phenotype: decreased CD5 + B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.Ann. Rheum. Dis.20157491784178610.1136/annrheumdis‑2014‑20675625934841
     [Google Scholar]
  92. NasrallahM. PouliotY. HartmannB. DunnP. ThomsonE. WiserJ. ButteA.J. Reanalysis of the Rituximab in ANCA-Associated Vasculitis trial identifies granulocyte subsets as a novel early marker of successful treatment.Arthritis Res. Ther.201517126210.1186/s13075‑015‑0778‑z26387933
     [Google Scholar]
  93. PepperR.J. DraibeJ.B. CaplinB. FervenzaF.C. HoffmanG.S. KallenbergC.G. LangfordC.A. MonachP.A. SeoP. SpieraR. William St ClairE. TchaoN.K. StoneJ.H. SpecksU. MerkelP.A. SalamaA.D. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3–antineutrophil cytoplasmic antibody–associated vasculitis.Arthritis Rheumatol.201769118519310.1002/art.3981427428710
     [Google Scholar]
  94. AlbericiF SmithRM FonsecaM WillcocksLC JonesRB HolleJU WieczorekS NeumannT MartoranaD GregoriniG Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis.J. Allergy Clin. Immunol.2017139516841687.e10
     [Google Scholar]
  95. PuchalaM. RydzewskiA. KowalikI. WisłowskaM. Comparison of granulomatosis with polyangiitis clinical features in patients depending on involvement or absence of kidney involvement.Curr. Rheumatol. Rev.202117437938910.2174/157339711766621072614375734313202
     [Google Scholar]
  96. DurelC.A. HotA. TrefondL. AumaitreO. PugnetG. SamsonM. AbadS. BelotA. Blanchard-DelaunayC. CohenP. Cohen-AubardF. CottinV. CrestaniB. MoreuilC.D. DuruptS. GarzaroM. GirszynN. GodeauB. HachullaE. JamillouxY. JegoP. KillianM. LazaroE. Le GallouT. LiozonE. MartinT. PapoT. PerlatA. PilletP. GuillevinL. TerrierB. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.Rheumatology (Oxford)20195891565157310.1093/rheumatology/kez07130887055
     [Google Scholar]
  97. PulleritsR. LjevakM. VikgrenJ. BokarewaM. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre.Scand. J. Immunol.201276441142010.1111/j.1365‑3083.2012.02747.x22823472
     [Google Scholar]
  98. OwczarczykK. CascinoM.D. HolwegC. TewG.W. OrtmannW. BehrensT. SchindlerT. LangfordC.A. St ClairE.W. MerkelP.A. SpieraR. SeoP. KallenbergC.G. SpecksU. LimN. StoneJ. BrunettaP. PrunottoM. Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis.JCI Insight2020518e13618010.1172/jci.insight.13618032841219
     [Google Scholar]
  99. DraibeJ. SalamaA.D. Association of ANCA associated vasculitis and rheumatoid arthritis: A lesser recognized overlap syndrome.Springerplus2015415010.1186/s40064‑015‑0835‑825664229
     [Google Scholar]
  100. ForayN. HudaliT. PapireddyM. GaoJ. A case report describing a rare presentation of simultaneous occurrence of MPO-ANCA-associated vasculitis and rheumatoid arthritis.Case Rep. Nephrol.201620161510.1155/2016/934052427891268
     [Google Scholar]
  101. ItikyalaS. PattanaikD. RazaS. Systemic Lupus Erythematosus (SLE) and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis (AAV) overlap syndrome: Case report and review of the literature.Case Rep. Rheumatol.201920191510.1155/2019/501390430723567
     [Google Scholar]
  102. HounokiH. ShinodaK. MatsuiA. OkumuraM. YamaguchiS. KakeshitaK. YamazakiH. KoikeT. MakinoT. TobeK. A Case of systemic lupus erythematosus and antineutrophil cytoplasmic antibodies-associated vasculitis overlap syndrome.Case Rep. Rheumatol.202120211610.1155/2021/669065833505756
     [Google Scholar]
  103. FarahR.I. ShahinN.A. AlawnehM. AdwanM. Rapidly progressive glomerulonephritis due to systemic lupus erythematosus and ANCA-associated vasculitis overlap.Lupus202029898398610.1177/096120332092036832316845
     [Google Scholar]
  104. WuH.H.L. WangC.C.Y. WoywodtA. PonnusamyA. Concurrent presentation of IgG4-related tubulointerstitial nephritis and ANCA MPO crescentic glomerulonephritis.Clin. Nephrol. Case Stud.2022101475310.5414/CNCS11085235837351
     [Google Scholar]
  105. SzilasiM. MátyusJ. FileI. SzücsG. RákócziÉ. PflieglerG. SzabóZ. VéghE. SzekaneczZ. Association of ANCA-associated vasculitis-rheumatoid arthritis overlap syndrome in four patients: Rituximab may be the right choice?Autoimmunity201245430430910.3109/08916934.2012.67707822443800
     [Google Scholar]
  106. HuangJ. WuL. HuangX. XieY. YuJ. YangJ. FangH. ZhangL. Successful treatment of dual-positive anti-myeloperoxidase and anti-glomerular basement membrane antibody vasculitis with pulmonary-renal syndrome.Case Rep. Nephrol. Dial.2016611710.1159/00044316326889474
     [Google Scholar]
  107. KantS. ShahA.A. HummersL.K. WigleyF.M. GeethaD. ANCA-associated vasculitis in scleroderma: A renal perspective
.Clin. Nephrol.201890641341810.5414/CN10944530106367
     [Google Scholar]
  108. PefanisA. WilliamsD.S. SkrzypekH. FungA. PaizisK. A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab.Obstet. Med.2020131414410.1177/1753495X1878085332284732
     [Google Scholar]
  109. KantS. MorrisA. RaviS. FloydL. GapudE. AntichosB. DhaygudeA. SeoP. GeethaD. The impact of COVID-19 pandemic on patients with ANCA associated vasculitis.J. Nephrol.202134118519010.1007/s40620‑020‑00881‑333034038
     [Google Scholar]
  110. KatariaS. RogersS. SadiaH. AliT. QureshiH.M. BanoS. AnigboC.L. SinghR. Antineutrophil Cytoplasmic Antibody (ANCA)-associated renal vasculitis after COVID-19 infection: A Case report.Cureus2022146e2611110.7759/cureus.2611135875289
     [Google Scholar]
  111. İnceB. BektaşM. KocaN. AğargünB.F. ZaraliS. GüzeyD.Y. DurakG. YalçinkayaY. Artim-EsenB. GülA. İnançM. Antineutrophil cytoplasmic antibody-associated vasculitis and COVID-19.J. Clin. Rheumatol.202228630030410.1097/RHU.000000000000185535612560
     [Google Scholar]
  112. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributorsSeverity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients.Ann. Rheum. Dis.202180452753810.1136/annrheumdis‑2020‑21831033268442
     [Google Scholar]
  113. McClureM.E. ZhuY. SmithR.M. GopaluniS. TieuJ. PopeT. KristensenK.E. JayneD.R.W. BarrettJ. JonesR.B. Long-term maintenance rituximab for ANCA-associated vasculitis: Relapse and infection prediction models.Rheumatology (Oxford)20216031491150110.1093/rheumatology/keaa54133141217
     [Google Scholar]
  114. Schulze-KoopsH. KruegerK. VallbrachtI. HasseliR. SkapenkoA. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.Ann. Rheum. Dis.2021805e6710.1136/annrheumdis‑2020‑21807532591357
     [Google Scholar]
  115. TepasseP.R. HafeziW. LutzM. KühnJ. WilmsC. WiewrodtR. SackarndJ. KellerM. SchmidtH.H. VollenbergR. Persisting SARS-CoV-2 viraemia after rituximab therapy: Two cases with fatal outcome and a review of the literature.Br. J. Haematol.2020190218518810.1111/bjh.1689632557623
     [Google Scholar]
  116. StrangfeldA. SchäferM. GianfrancescoM.A. Lawson-ToveyS. LiewJ.W. LjungL. MateusE.F. RichezC. SantosM.J. SchmajukG. ScirèC.A. SirotichE. SparksJ.A. SufkaP. ThomasT. TrupinL. WallaceZ.S. Al-AdelyS. Bachiller-CorralJ. BhanaS. CacoubP. CarmonaL. CostelloR. CostelloW. GossecL. GraingerR. HachullaE. HasseliR. HausmannJ.S. HyrichK.L. IzadiZ. JacobsohnL. KatzP. Kearsley-FleetL. RobinsonP.C. YazdanyJ. MachadoP.M. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry.Ann. Rheum. Dis.202180793094210.1136/annrheumdis‑2020‑21949833504483
     [Google Scholar]
  117. HabermanR. AxelradJ. ChenA. CastilloR. YanD. IzmirlyP. NeimannA. AdhikariS. HudesmanD. ScherJ.U. Covid-19 in immune-mediated inflammatory diseases - Case series from New York.N. Engl. J. Med.20203831858810.1056/NEJMc200956732348641
     [Google Scholar]
  118. CombesA.J. CourauT. KuhnN.F. HuK.H. RayA. ChenW.S. ChewN.W. ClearyS.J. KushnoorD. ReederG.C. ShenA. TsuiJ. Hiam-GalvezK.J. Muñoz-SandovalP. ZhuW.S. LeeD.S. SunY. YouR. MagnenM. RodriguezL. ImK.W. SerwasN.K. LeligdowiczA. ZamecnikC.R. LoudermilkR.P. WilsonM.R. YeC.J. FragiadakisG.K. LooneyM.R. ChanV. WardA. CarrilloS. CathyC. ZhanJ. SamadB. ChakS. GhaleR. GibersonJ. GonzalezA. JaureguiA. LeeD. NguyenV. YeeK. Abe-JonesY. PierceL. PrasadP. SinhaP. BeagleA. LeaT. EsmaliiA. SigmanA. OrtizG.M. RaffelK. JonesC. LiuK. EckalbarW. MatthayM. ErleD.J. WoodruffP.G. LangelierC. KangelarisK. HendricksonC.M. CalfeeC. RaoA.A. KrummelM.F. Global absence and targeting of protective immune states in severe COVID-19.Nature2021591784812413010.1038/s41586‑021‑03234‑733494096
     [Google Scholar]
  119. GuilpainP. Le BihanC. FoulongneV. TaourelP. PansuN. MariaA.T.J. JungB. LarcherR. KloucheK. Le MoingV. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: Lessons from a case with severe pneumonia.Ann. Rheum. Dis.2021801e1010.1136/annrheumdis‑2020‑21754932312768
     [Google Scholar]
  120. FalletB. KyburzD. WalkerU.A. Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment.Arthritis Rheumatol.20207291581158210.1002/art.4138032458534
     [Google Scholar]
  121. KoppC.R. NaiduG.S.R.S.N.K. MisraD.P. DeoP. JakullaR.S. MakanK. MaharajA. AgarwalV. SharmaA. Managing ANCA-associated vasculitis during the COVID-19 pandemic: Results from an online survey.Rheumatol. Int.202141111941194710.1007/s00296‑021‑04975‑434427760
     [Google Scholar]
  122. WatanabeT. Vasculitis following influenza vaccination: A review of the literature.Curr. Rheumatol. Rev.201713318819628521688
     [Google Scholar]
  123. QuartuccioL. TreppoE. BinuttiM. Del FrateG. De VitaS. Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis.Rheumatology (Oxford)20216073476347710.1093/rheumatology/keab17533609106
     [Google Scholar]
  124. ShakoorM.T. BirkenbachM.P. LynchM. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine.Am. J. Kidney Dis.202178461161310.1053/j.ajkd.2021.06.01634280507
     [Google Scholar]
  125. VillaM. Díaz-CrespoF. Pérez de JoséA. VerdallesÚ. VerdeE. Almeida RuizF. AcostaA. MijaylovaA. GoicoecheaM. A case of ANCA-associated vasculitis after AZD1222 (Oxford–AstraZeneca) SARS-CoV-2 vaccination: Casualty or causality?Kidney Int.2021100493793810.1016/j.kint.2021.07.02634416184
     [Google Scholar]
  126. ChenC.C. ChenH.Y. LuC.C. LinS.H. Case Report: Anti-neutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage may occur after COVID-19 vaccination.Front. Med. (Lausanne)20218219576544710.3389/fmed.2021.76544734859017
     [Google Scholar]
  127. MoorM.B. Suter-RinikerF. HornM.P. AeberliD. AmslerJ. MöllerB. NjueL.M. MedriC. Angelillo-ScherrerA. BorradoriL. Radonjic-HoesliS. Seyed JafariS.M. ChanA. HoepnerR. BacherV.U. ManiL.Y. IypeJ.M. HirzelC. MaurerB. SidlerD. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigator-initiated, single-centre, open-label study.Lancet Rheumatol.2021311e789e79710.1016/S2665‑9913(21)00251‑434514436
     [Google Scholar]
  128. WindpesslM. BruchfeldA. AndersH.J. KramerH. WaldmanM. ReniaL. NgL.F.P. XingZ. KronbichlerA. COVID-19 vaccines and kidney disease.Nat. Rev. Nephrol.202117529129310.1038/s41581‑021‑00406‑633558753
     [Google Scholar]
  129. ChoiB. ChoudharyM.C. ReganJ. SparksJ.A. PaderaR.F. QiuX. SolomonI.H. KuoH.H. BoucauJ. BowmanK. AdhikariU.D. WinklerM.L. MuellerA.A. HsuT.Y.T. DesjardinsM. BadenL.R. ChanB.T. WalkerB.D. LichterfeldM. BriglM. KwonD.S. KanjilalS. RichardsonE.T. JonssonA.H. AlterG. BarczakA.K. HanageW.P. YuX.G. GaihaG.D. SeamanM.S. CernadasM. LiJ.Z. Persistence and evolution of SARS-CoV-2 in an immunocompromised host.N. Engl. J. Med.2020383232291229310.1056/NEJMc203136433176080
     [Google Scholar]
  130. FriedmanM.A. WinthropK.L. Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab.Ann. Rheum. Dis.20218081102110410.1136/annrheumdis‑2021‑22008833674264
     [Google Scholar]
  131. FriedmanM.A. WinthropK.L. Vaccines and disease-modifying antirheumatic drugs.Rheum. Dis. Clin. North Am.201743111310.1016/j.rdc.2016.09.00327890167
     [Google Scholar]
  132. BruchfeldA. KronbichlerA. AlbericiF. FervenzaF.C. JayneD.R.W. SegelmarkM. TesarV. SzpirtW.M. COVID-19 and ANCA-associated vasculitis: Recommendations for vaccine preparedness and the use of rituximab.Nephrol. Dial. Transplant.20213691758176010.1093/ndt/gfab17433944946
     [Google Scholar]
  133. KantS. AzarA. GeethaD. Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.Kidney Int.202110.1016/j.kint.2021.08.02034822874
     [Google Scholar]
  134. PozzettoB. LegrosV. DjebaliS. BarateauV. GuibertN. VillardM. PeyrotL. AllatifO. FassierJ.B. Massardier-PilonchéryA. Brengel-PesceK. Yaugel-NovoaM. DenollyS. BosonB. BourletT. BalA. ValetteM. AndrieuT. LinaB. SakerK. CompagnonC. MokdadB. d’AubaredeC. PitiotV. EscuretV. MorfinF. TrabaudM-A. PrieuxM. DuboisV. JossetL. DanielS. CossetF-L. PaulS. DefranceT. MarvelJ. WalzerT. Trouillet-AssantS. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination.Nature2021600789070170610.1038/s41586‑021‑04120‑y34673755
     [Google Scholar]
  135. van DaalenE.E. RizzoR. KronbichlerA. WolterbeekR. BruijnJ.A. JayneD.R. BajemaI.M. RahmattullaC. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.Ann. Rheum. Dis.20177661064106910.1136/annrheumdis‑2016‑20992527899372
     [Google Scholar]
  136. FlossmannO. BerdenA. de GrootK. HagenC. HarperL. HeijlC. HöglundP. JayneD. LuqmaniR. MahrA. MukhtyarC. PuseyC. RasmussenN. StegemanC. WalshM. WestmanK. Long-term patient survival in ANCA-associated vasculitis.Ann. Rheum. Dis.201170348849410.1136/ard.2010.13777821109517
     [Google Scholar]
/content/journals/cdt/10.2174/0113894501323529240910015912
Loading
Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis
Curr Drug Targets 26, 73 (2025); https://doi.org/10.2174/0113894501323529240910015912
/content/journals/cdt/10.2174/0113894501323529240910015912
/content/journals/cdt/10.2174/0113894501323529240910015912
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Immunopharmacology; MPO-associated vasculitis; PR3-associated vasculitis; Rituximab; small vessel vasculitis; wegner

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test